Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
Financial Figures/Balance Sheet
Intercell announces preliminary Q4 and full-year 2008 results

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
9-month report
02.03.2009
» Increased profitability and strong financial position for full-year
2008 » Excellent progress in late-stage pipeline products » Vaccine 
to prevent Japanese Encephalitis approved in Australia
Vienna (Austria), March 2, 2009 - Today, the biotech-vaccine company 
Intercell AG (VSE: ICLL) announced its preliminary financial results 
for the fourth quarter and the full financial year 2008, and 
presented an update on the Company's development programs.
Driven by strong revenues of EUR 30.5 m in the fourth quarter and 
income tax effects, Intercell´s profit for the full year 2008 was EUR
17.2 m, compared to EUR 5.0 m in the prior year. The annual revenues 
increased from EUR 53.3 m in the year ended December 31, 2007 to EUR 
55.8 m in the year ended December 31, 2008. R&D costs for the full 
year 2008 increased to EUR 56.1 m and enabled the strong progression 
of Intercell's late-stage pipeline, including the advanced clinical 
programs acquired with Iomai Corporation. Cash and marketable 
securities of EUR 190.9 m at year-end give Intercell a strong 
financial position and will allow aggressive investment in late-stage
pipeline products.
Intercell's vaccine to prevent Japanese Encephalitis, IXIARO®, 
received positive CHMP opinion in Europe and product approval in 
Australia, with U.S. approval expected in the near future. No 
additional requests or comments from the authorities are pending; 
hence the remaining administrative steps are expected to be concluded
soon. "We have successfully managed to market our first vaccine and 
therefore reached one of the most important milestones in the 
Company's history - Intercell has proven its ability to develop and 
produce a product for global markets. With this achievement, we are 
looking forward to initiating a new growth phase for our company," 
said Intercell Chief Executive Officer Gerd Zettlmeissl.
DEVELOPMENT PROGRAMS AND PRODUCT PIPELINE
Aggressive investment in four late-stage pipeline products with 
clinical efficacy results expected within the next 12 months for 
Travelers Diarrhea vaccine patch, Staphylococcus aureus (S. aureus) 
vaccine candidate, and Pseudomonas vaccine candidate and Pandemic 
Influenza
» Traveler's Diarrhea patch vaccine - Recruitment of pivotal Phase 
III has   begun and initiation of Phase III clinical trial planned 
for traveling   season in H1 2009
» S. aureus vaccine - Merck & Co., Inc. has advanced the clinical 
efficacy   trial in cardiothoracic surgery patients and efficacy data
is expected mid   2009. The program was expanded with an additional 
Phase II study in   hemodialysis patients with late-stage kidney 
disease
» Pseudomonas aeruginosa vaccine - Phase II clinical trial in 
mechanically   ventilated intensive care patients has been initiated-
First efficacy data   is expected H2 2009
» Pandemic Influenza Vaccine Enhancement Patch - Program has been 
granted   additional funding of USD 12.5 m by U.S. Department of 
Health and Human   Services (HHS) - Start of Phase II is planned for 
H1 2009
» Streptococcus pneumoniae vaccine - Phase I clinical trial start 
with vaccine   candidate to prevent infections with the bacterium 
Streptococcus pneumoniae   is planned for March 2009
» herapeutic Hepatitis C vaccine - Initiation of next clinical trials
will take   advantage of a combination treatment and the use of IC31®
as more potent   adjuvant - strategic partnering process ongoing
» Tuberculosis vaccine - Phase I/II clinical development program of 
Statens   Serum Institut (SSI), Intercell and Sanofi Pasteur is 
proceeding according   to plan
» Group B Streptococcus vaccine - program has been licensed to 
Novartis
KEY FINANCIAL INFORMATION
in EUR thousands
                                  Year ended December 31,
                            2008           2007           2006
Revenues                   55,763         53,349         23,452
Net profit/(loss)          17,175          5,009        (16,143)
Net operating cash flow   (10,186)        41,686         (7,979)
Cash and marketable
securities, end of the
year                       190,865        287,571         94,421
For the full report please visit www.intercell.com
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG